Structural features of selenate based {Mo132} keplerate capsules

New nanosized keplerate [{Mo6O21(H2O)6}12{Mo2O4(SeO4)}30]72– was prepared by ligand substitution in the corresponding acetate complex in the presence of ammonium selenate. Three novel keplerate-type compounds (NH4)72[{Mo6O21(H2O)6}12{Mo2O4(SeO4)}30]·250H2O (2), [C(NH2)3]72[{Mo6O21(H2O)6}12{Mo2O4(SeO4)}30]·250H2O (3) and (NH4)36(NMe2H2)36[{Mo6O21(H2O)6}12{Mo2O4(SeO4)}30]·250H2O...

Antidiabetic and antioxidative properties of novel Zn(II)-cinnamic acid complex

Background: The role of zinc in diabetes has been a subject of considerable interest, due to the insulin mimetic properties associated with this mineral. On the other hand, phenolic acids are known plant-derived polyphenols with antioxidative and antidiabetic pharmacological credence. Objective: This study was done to develop a novel therapeutic nutraceutical with an improved and multi-mode antidiabetic and antioxidative pharmacological property using cinnamic acid and Zn(II) mineral framework. Methods: A Zn(II) acetate complex of cinnamic acid was synthesized and characterized using FT-IR and 1 HNMR spectroscopy. Cytotoxicity evaluation was done using Chang liver cells and differentiated L6 myotubes. DPPH and ABTS scavenging as well as Fe3+ reducing effects where used to evaluate the antioxidant capacity. The antiglycation as well as αglucosidase and α-amylase inhibitory properties where evaluated. Insulin mimetic property was evaluated as glucose uptake in L6 myotubes, while the complex was docked against GLUT-4 and PKB. Results: FTIR and 1 HMR suggested that Zn(II) complexed with cinnamic acid through a Zn(O4) coordination mode, thus affording the resulting complex 2 cinnamic acid molecules. Hence, complexation increased (p 0.05) the antiglycation effect of cinnamic acid (IC50 = 29.3 µM) by 2 folds (IC50 = 13.9 µM). Also, Zn(II) conferred a potent glucose uptake (EC50 = 31 µM) and α-glucosidase inhibitory (IC50 = 59.4 µM) property on cinnamic acid, hence the activity of the complex was 162 and 2.1 folds higher than (p 0.05) its precursor, respectively. Further molecular docking studies showed that the complex had a stronger interaction with insulin signaling proteins (GLUT-4 and PKB) than its precursor. Interestingly, the complex showed no severe cytotoxicity. Conclusion: Data suggested a structure-activity relationship. Complexation of Zn(II) to cinnamic acid resulted in a complex with improved and multi-facet pharmacological effects, which may be further studied as a safe glycemic control nutraceutical for T2D and glycation-induced complication.

Gas-Phase Reactions of the Group 10 Organometallic Cations, [(phen)M(CH3)]+ with Acetone: Only Platinum Promotes a Catalytic Cycle via the Enolate [(phen)Pt(OC(CH2)CH3)]+

Electrospray ionisation of the ligated group 10 metal complexes [(phen)M(O2CCH3)2] (M = Ni, Pd, Pt) generates the cations [(phen)M(O2CCH3)]+, whose gas-phase chemistry was studied using multistage mass spectrometry experiments in an ion trap mass spectrometer with the combination of collision-induced dissociation (CID) and ion-molecule reactions (IMR). A new catalytic cycle has been discovered. In step 1, decarboxylation of [(phen)M(O2CCH3)]+ under CID conditions generates the organometallic cations [(phen)M(CH3)]+, which react with acetone to generate the [(phen)M(CH3)(OC(CH3)2)]+ adducts in competition with formation of the coordinated enolate for M = Pt (step 2). For M = Ni and Pd, the adducts regenerate [(phen)M(CH3)]+ upon CID. In the case of M = Pt, loss of methane is favored over loss of acetone and results in the formation of the enolate complex, [(phen)Pt(OC(CH2)CH3)]+. Upon further CID, both methane and CO loss can be observed resulting in the formation of the ketenyl and ethyl complexes [(phen)Pt(OCCH)]+ and [(phen)Pt(CH2CH3)]+ (step 3), respectively. In step 4, CID of [(phen)Pt(CH2CH3)]+ results in a beta-hydride elimination reaction to yield the hydride complex, [(phen)Pt(H)]+, which reacts with acetic acid to regenerate the acetate complex [(phen)Pt(O2CCH3)]+ and H2 in step 5. Thus, the catalytic cycle is formally closed, which corresponds to the decomposition of acetone and acetic acid into methane, CO, CO2, ethene and H2. All except the last step of the catalytic cycle are modelled using DFT calculations with optimizations of structures at the M06/SDD 6-31G(d) level of theory.

Synthesis, crystal structure and biological activity of 6-(3-chloropropoxy)-4-(2-fluorophenylamino)-7-methoxyquinazoline

The title compound, 6-(3-chloropropoxy)-4-(2-fluorophenylamino)-7-methoxyquinazoline, was synthesized by selective nucleophilic attack at C-1 of 1-bromo-3-chloropropane by the potassium salt of 4-(2-fluorophenylamino)-7-methoxyquinazolin-6-ol, which was prepared from 7-methoxy-4-oxo-3,4-dihydroquinazolin-6-yl acetate in three steps. The compound crystallized as an ethyl acetate complex (C20H21ClFN3O3, Mr = 405.85), and X-ray crystallography showed that the crystal belongs to the orthorhombic system, space group Pbca with a = 12.7407(4) Å, b = 14.0058(5) Å, c = 21.7726(7) Å, α = 90°, β = 90° and γ = 90°. The whole molecule is stacked into a three-dimensional structure via weak N–H…N hydrogen bonding between molecules. The compound acts as an effective inhibitor on the proliferation of a lung cancer cell line.